Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.37 |
| ▸ | PARP1 | P09874 | 5/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.32 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | F3 | P13726 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865736 | 0.76 | ALDH1A1 (0.38) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL30664964 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL7657136 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL652655 | 0.71 | PARP10 (0.43) | HTR2AHTR2CHTR2BPARP10PARP1 | |
| SCHEMBL31393728 | 0.69 | PARP10 (0.42) | HTR2AHTR2CHTR2BPARP10PARP11 | |
| SCHEMBL22993473 | 0.69 | PNMT (0.54) | HTR2AHTR2CHTR2BPNMTASIC3 | |
| SCHEMBL29407560 | 0.69 | PNMT (0.54) | HTR2AHTR2CHTR2BPNMTASIC3 | |
| SCHEMBL13035941 | 0.68 | FABP6 (0.41) | ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL23727152 | 0.68 | PNMT (0.53) | HTR2AHTR2CHTR2BPNMTASIC3 | |
| SCHEMBL23384836 | 0.68 | NOTUM (0.46) | HTR2AHTR2CHTR2BPARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | AXONIS THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024006379-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | AXONIS THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | HTR2A 3636/4885HTR2C 3925/4885HTR2B 4282/4885 |
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | PRKCSH, MAPK7, PRKCB | HTR2A 4581/4885HTR2C 3132/4885HTR2B 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.